The ASP and C5L2 pathway: Another bridge between inflammation and metabolic homeostasis

Clinical Lipidology

Volumn 5, Issue 3, 2010, Pages 367-377

  Fisette, Alexandre ^a   Cianflone, Katherine ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

acylation stimulating protein; adipokine; atherosclerosis; C5L2; complement system; inflammation; obesity; Type 2 diabetes

Indexed keywords

ACYLATION STIMULATING PROTEIN; ADIPOCYTOKINE; G PROTEIN COUPLED RECEPTOR; PROTEIN C5L2; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; COMPLEMENT SYSTEM; HOMEOSTASIS; HORMONE RELEASE; HUMAN; IMMUNE SYSTEM; INFLAMMATION; LIPID STORAGE; METABOLIC DISORDER; METABOLIC HOMEOSTASIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 77953862777     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/clp.10.21     Document Type: Review

References (87)

1. Cianflone KM, Sniderman AD, Walsh MJ, Vu HT, Gagnon J, Rodriguez MA: Purification and characterization of acylation stimulating protein. J. Biol. Chem. 264(1), 426-430 (1989).
2. Cianflone K, Xia ZN, Chen LY: Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim. Biophys. Acta 1609(2), 127-143 (2003).
3. Choy LN, Rosen BS, Spiegelman BM: Adipsin and an endogenous pathway of complement from adipose-cells. J. Biol. Chem. 267(18), 12736-12741 (1992).
4. Kalant D, Cain SA, Maslowska M, Sniderman AD, Cianflone K, Monk PN: The chemoattractant receptor-like protein C5L2 binds the C3a des-Arg(77)/acylation- stimulating protein. J. Biol. Chem. 278(13), 11123-11129 (2003).
5. Kalant D, MacLaren R, Cui W et al.: C5L2 is a functional receptor for acylation-stimulating protein. J. Biol. Chem. 280(25), 23936-23944 (2005).
6. Cui W, Lapointe M, Gauvreau D, Kalant D, Cianflone K: Recombinant C3adesArg/ acylation stimulating protein (ASP) is highly bioactive: a critical evaluation of C5L2 binding and 3T3-L1 adipocyte activation. Mol. Immunol. 46(16), 3207-3217 (2009).
7. Yasruel Z, Cianflone K, Sniderman AD, Rosenbloom M, Walsh M, Rodriguez MA: Effect of acylation stimulating protein on the triacylglycerol synthetic pathway of human adipose-tissue. Lipids 26(7), 495-499 (1991).
8. Faraj M, Sniderman AD, Cianflone K: ASP enhances in situ lipoprotein lipase activity by increasing fatty acid trapping in adipocytes. J. Lipid Res. 45(4), 657-666 (2004).
9. Van Hermelen V, Reynisdottir S, Cianflone K et al.: Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation-stimulating protein and insulin. J. Biol. Chem. 274(26), 18243-18251 (1999).
10. Maslowska M, Sniderman AD, Germinario R, Cianflone K: ASP stimulates glucose transport in cultured human adipocytes. Int. J. Obes. 21(4), 261-266 (1997).
11. Tao YH, Cianflone K, Sniderman AD, Colby SP, Germinario RJ: Acylation-stimulating protein (ASP) regulates glucose transport in the rat L6 muscle cell line. Biochim. Biophys. Acta 1344(3), 221-229 (1997).
12. Maslowska M, Legakis H, Assadi F, Cianflone K: Targeting the signaling pathway of acylation stimulating protein. J. Lipid Res. 47(3), 643-652 (2006).
13. Maslowska M, Vu H, Phelis S et al.: Plasma acylation stimulating protein, adipsin and lipids in non-obese and obese populations. Eur. J. Clin. Invest. 29(8), 679-686 (1999).
14. Paglialunga S, Julien P, Cianflone K: The role of acylation stimulating protein in lipoprotein lipase deficiency. Obesity 16, S171 (2008).
15. Muscari A, Antonelli S, Bianchi G et al.: Serum C3 is a stronger inflammatory marker of insulin resistance than C-reactive protein, leukocyte count, and erythrocyte sedimentation rate - comparison study in an elderly population. Diabetes Care 30(9), 2362-2368 (2007).
16. Cianflone K, Zhang XJ, Genest J, Sniderman A: Plasma acylation- stimulating protein in coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 17(7), 1239-1244 (1997).
17. Yang Y, Lu HL, Zhang J et al.: Relationships among acylation stimulating protein, adiponectin and complement C3 in lean vs obese Type 2 diabetes. Int. J. Obes. 30(3), 439-446 (2006).
18. Schrauwen P, Hesselink MKC, Jain M, Cianflone K: Acylation-stimulating protein: effect of acute exercise and endurance training. Int. J. Obes. 29(6), 632-638 (2005).
19. Tahiri Y, Karpe F, Tan GD, Cianflone K: Rosiglitazone decreases postprandial production of acylation stimulating protein in Type 2 diabetics. Nutr. Metab. 4, 11 (2007).
20. Cianflone K, Zakarian R, Couillard C, Delplanque B, Despres JP, Sniderman A: Fasting acylation-stimulating protein is predictive of postprandial triglyceride clearance. J. Lipid Res. 45(1), 124-131 (2004).
21. Roy C, Paglialunga S, Fisette A et al.: Shift in metabolic fuel in acylation-stimulating protein-deficient mice following a high-fat diet. Am. J. Physiol. Endocrinol. Metab. 294(6), E1051-E1059 (2008).
22. Xia ZN, Stanhope KL, Digitale E et al.: Acylation-stimulating protein (ASP)/ complement C3adesArg deficiency results in increased energy expenditure in mice. J. Biol. Chem. 279(6), 4051-4057 (2004).
23. Murray I, Sniderman AD, Cianflone K: Enhanced triglyceride clearance with intraperitoneal human acylation stimulating protein in C57BL/6 mice. Am. J. Physiol. Endocrinol. Metab. 277(3), E474-E480 (1999). (Pubitemid 29458207)
24. Xia Z, Sniderman AD, Cianflone K: Acylation-stimulating protein (ASP) deficiency induces obesity resistance and increased energy expenditure in ob/ob mice. J. Biol. Chem. 277(48), 45874-45879 (2002).
25. Paglialunga S, Schrauwen P, Roy C et al.: Reduced adipose tissue triglyceride synthesis and increased muscle fatty acid oxidation in C5L2 knockout mice. J. Endocrinol. 194(2), 293-304 (2007).
26. Cui W, Paglialunga S, Kalant D et al.: Acylation-stimulating protein/C5L2- neutralizing antibodies alter triglyceride metabolism in vitro and in vivo. Am. J. Physiol. Endocrinol. Metab. 293(6), E1482-E1491 (2007).
27. Hotamisligil GS: Inflammation and metabolic disorders. Nature 444(7121), 860-867 (2006).
28. MacLaren R, Cui W, Cianflone K: Adipokines and the immune system: an adipocentric view. Adv. Exp. Med. Biol. 632, 1-21 (2008).
29. Bastard JP, Maachi M, Lagathu C et al.: Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw. 17(1), 4-12 (2006).
30. Lumeng CN, Bodzin JL, Saltiel AR: Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J. Clin. Invest. 117(1), 175-184 (2007).
31. Bourlier V, Zakaroff-Girard A, Miranville A et al.: Remodeling phenotype of human subcutaneous adipose tissue macrophages. Circulation 117(6), 806-815 (2008).
32. Harboe M, Mollnes TE: The alternative complement pathway revisited. J. Cell. Mol. Med. 12(4), 1074-1084 (2008).
33. Haas PJ, Van Strijp J: Anaphylatoxins - their role in bacterial infection and inflammation. Immunol. Res. 37(3), 161-175 (2007).
34. Monk PN, Scola AM, Madala P, Fairlie DP: Function, structure and therapeutic potential of complement C5a receptors. Br. J. Pharmacol. 152(4), 429-448 (2007).
35. Klos A, Tenner AJ, Johswich KO, Ager RR, Reis ES, Kohl J: The role of the anaphylatoxins in health and disease. Mol. Immunol. 46(14), 2753-2766 (2009).
36. Bokisch VA, Mullereb HJ: Anaphylatoxin inactivator of human plasma - its isolation and characterization as a carboxypeptidase. J. Clin. Invest. 49(12), 2427-2436 (1970).
37. Boulay F, Mery L, Tardif M, Brouchon L, Vignais P: Expression cloning of a receptor for C5A anaphylatoxin on differentiated Hl-60 Cells. Biochemistry 30(12), 2993-2999 (1991).
38. Gerard NP, Gerard C: The chemotactic receptor for human-C5A anaphylatoxin. Nature 349(6310), 614-617 (1991).
39. Ames RS, Li Y, Sarau HM et al.: Molecular cloning and characterization of the human anaphylatoxin C3a receptor. J. Biol. Chem. 271(34), 20231-20234 (1996).
40. Crass T, Raffetseder U, Martin U et al.: Expression cloning of the human C3a anaphylatoxin receptor (C3aR) from differentiated U-937 cells. Eur. J. Immunol. 26(8), 1944-1950 (1996).
41. Roglic A, Prossnitz ER, Cavanagh SL, Pan ZX, Zou AH, Ye RD: cDNA cloning of a novel G protein-coupled receptor with a large extracellular loop structure. Biochim. Biophys. Acta 1305(1-2), 39-43 (1996).
42. Ohno M, Hirata T, Enomoto M, Araki T, Ishimaru H, Takahashi TA: A putative chemoattractant receptor, C5L2, is expressed in granulocyte and immature dendritic cells, but not in mature dendritic cells. Mol. Immunol. 37(8), 407-412 (2000).
43. Zwirner J, Fayyazi A, Gotze O: Expression of the anaphylatoxin C5a receptor in non-myeloid cells. Mol. Immunol. 36(13-14), 877-884 (1999).
44. Gao HW, Neff TA, Guo RF et al.: Evidence for a functional role of the second C5a receptor C5L2. FASEB J. 19(3), 1003-1005 (2005).
45. Mamane Y, Chan CC, Lavallee G et al.: The C3a anaphylatoxin receptor is a key mediator of insulin resistance and functions by modulating adipose tissue macrophage infiltration and activation. Diabetes 58(9), 2006-2017 (2009).
46. Chen NJ, Mirtsos C, Suh D et al.: C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature 446(7132), 203-207 (2007).
47. Ward PA: Functions of C5a receptors. J. Mol. Med. 87(4), 375-378 (2009).
48. Cain SA, Monk PN: The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg(74). J. Biol. Chem. 277(9), 7165-7169 (2002).
49. Johswich K, Martin M, Thalmann J, Rheinheimer C, Monk PN, Klos A: Ligand specificity of the anaphylatoxin C5L2 receptor and its regulation on myeloid and epithelial cell lines. J. Biol. Chem. 281(51), 39088-39095 (2006).
50. Gerard NP, Lu B, Liu PX et al.: An anti-inflammatory function for the complement anaphylatoxin C5a-binding protein, C5L2. J. Biol. Chem. 280(48), 39677-39680 (2005).
51. Scola AM, Johswich KO, Morgan BP, Klos A, Monk PN: The human complement fragment receptor, C5L2, is a recycling decoy receptor. Mol. Immunol. 46(6), 1149-1162 (2009).
52. Geva A, Lassere TB, Lichtarge O, Pollitt SK, Baranski TJ: Genetic mapping of the human C5a receptor - identification of transmembrane amino acids critical for receptor function. J. Biol. Chem. 275(45), 35393-35401 (2000).
53. Floyd DH, Geva A, Bruinsma SP, Overton MC, Blumer KJ, Baranski TJ: C5a receptor oligomerization - II. Fluorescence resonance energy transfer studies of a human G protein-coupled receptor expressed in yeast. J. Biol. Chem. 278(37), 35354-35361 (2003).
54. Klco JM, Lassere TB, Baranski TJ: C5a receptor oligomerization - I. Disulfide trapping reveals oligomers and potential contact surfaces in a G protein-coupled receptor. J. Biol. Chem. 278(37), 35345-35353 (2003).
55. Hopken UE, Lu B, Gerard NP, Gerard C: Impaired inflammatory responses in the reverse arthus reaction through genetic deletion of the C5a receptor. J. Exp. Med. 186(5), 749-756 (1997).
56. Karp CL, Grupe A, Schadt E et al.: Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma. Nat. Immunol. 1(3), 221-226 (2000).
57. Rittirsch D, Flierl MA, Nadeau BA et al.: Functional roles for C5a receptors in sepsis. Nat. Med. 14(5), 551-557 (2008).
58. Proctor LM, Woodruff TM, Taylor SM: Recent developments in C5/C5a inhibitors. Expert Opin. Ther. Pat. 16(4), 445-458 (2006).
59. Wenderfer SE, Wang HY, Ke BZ, Wetsel RA, Braun MC: C3a receptor deficiency accelerates the onset of renal injury in the MRL/Ipr mouse. Mol. Immunol. 46(7), 1397-1404 (2009).
60. Drouin SM, Corry DB, Hollman TJ, Kildsgaard J, Wetsel RA: Absence of the complement anaphylatoxin C3a receptor suppresses Th2 effector functions in a murine model of pulmonary allergy. J. Immunol. 169(10), 5926-5933 (2002).
61. Kildsgaard J, Hollmann TJ, Matthews KW, Bian K, Murad F, Wetsel RA: Cutting edge: targeted disruption of the C3a receptor gene demonstrates a novel protective anti-inflammatory role for C3a in endotoxin-shock. J. Immunol. 165(10), 5406-5409 (2000).
62. Boos L, Campbell LL, Ames R, Wetsel RA, Barnum SR: Deletion of the complement anaphylatoxin C3a receptor attenuates, whereas ectopic expression of C3a in the brain exacerbates, experimental autoimmune encephalomyelitis. J. Immunol. 173(7), 4708-4714 (2004).
63. Qu H, Ricklin D, Lambris JD: Recent developments in low molecular weight complement inhibitors. Mol. Immunol. 47(2-3), 185-195 (2009).
64. Van Lith LHC, Oosterom J, Van Elsas A, Zaman GJR: C5a-stimulated recruitment of b-arresting to the nonsignaling 7-transmembrane decoy receptor C5L2. J. Biomol. Screen. 14(9), 1067-1075 (2009).
65. Gao ZG, Hwang D, Bataille F et al.: Serine phosphorylation of insulin receptor substrate 1 by inhibitor kB kinase complex. J. Biol. Chem. 277(50), 48115-48121 (2002).
66. Glass CK, Ogawa S: Combinatorial roles of nuclear receptors in inflammation and immunity. Nat. Rev. Immunol. 6(1), 44-55 (2006).
67. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS: TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 116(11), 3015-3025 (2006).
68. Aguirre V, Uchida T, Yenush L, Davis R, White MF: The c-Jun NH2- terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J. Biol. Chem. 275(12), 9047-9054 (2000).
69. Griffin ME, Marcucci MJ, Cline GW et al.: Free fatty acid-induced insulin resistance is associated with activation of protein kinase C t and alterations in the insulin signaling cascade. Diabetes 48(6), 1270-1274 (1999).
70. Waetzig V, Herdegen T: Context-specific inhibition of JNKs: overcoming the dilemma of protection and damage. Trends Pharmacol. Sci. 26(9), 455-461 (2005).
71. Lago F, Dieguez C, Gomez-Reino J, Gualillo O: The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev. 18(3-4), 313-325 (2007). (Pubitemid 46891288)
72. Hotamisligil GS, Spiegelman BM: Tumor-necrosis-factor-a - a key component of the obesity-diabetes link. Diabetes 43(11), 1271-1278 (1994).
73. Harmon CM, Abumrad NA: Binding of sulfosuccinimidyl fatty-acids to adipocyte membrane-proteins - isolation and amino-terminal sequence of an 88-kd protein implicated in transport of long-chain fatty-acids. J. Membr. Biol. 133(1), 43-49 (1993).
74. Savill J, Hogg N, Haslett C: Macrophage vitronectin receptor, Cd36, and thrombospondin cooperate in recognition of neutrophils undergoing programmed cell-death. Chest 99(3), S6-S7 (1991).
75. Steppan CM, Bailey ST, Bhat S et al.: The hormone resistin links obesity to diabetes Nature. 409(6818), 307-312 (2001).
76. Holcomb IN, Kabakoff RC, Chan B et al.: FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J. 19(15), 4046-4055 (2000).
77. Coenen KR, Gruen ML, Chait A, Hasty AH: Diet-induced increases in adiposity, but not plasma lipids, promote macrophage infiltration into white adipose tissue. Diabetes 56(3), 564-573 (2007).
78. Chung S, LaPoint K, Martinez K, Kennedy A, Sandberg MB, McIntosh MK: Preadipocytes mediate lipopolysaccharide-induced inflammation and insulin resistance in primary cultures of newly differentiated human adipocytes. Endocrinology 147(11), 5340-5351 (2006).
79. Weyer C, Foley JE, Bogardus C, Tataranni PA, Pratley RE: Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts Type II diabetes independent of insulin resistance. Diabetologia 43(12), 1498-1506 (2000).
80. Maslowska M, Wang HW, Cianflone K: Novel roles for acylation stimulating prote in/C3adesArg: a review of recent in vitro and in vivo evidence. Vitam. Horm. 70, 309-332 (2005).
81. Paglialunga S, Fisette A, Yan YF et al.: Acylation-stimulating protein deficiency and altered adipose tissue in alternative complement pathway knockout mice. Am. J. Physiol. Endocrinol. Metab. 294(3), E521-E529 (2008).
82. Saleh J, Summers LKM, Cianflone K, Fielding BA, Sniderman AD, Frayn KN: Coordinated release of acylation stimulating protein (ASP) and triacylglycerol clearance by human adipose tissue in vivo in the postprandial period. J. Lipid Res. 39(4), 884-891 (1998).
83. Kalant D, Phelis S, Fielding BA, Frayn KN, Cianflone K, Sniderman AD: Increased postprandial fatty acid trapping in subcutaneous adipose tissue in obese women. J. Lipid Res. 41(12), 1963-1968 (2000).
84. He SQ, Atkinson C, Qiao F, Cianflone K, Chen XP, Tomlinson S: A complement-dependent balance between hepatic ischemia/reperfusion injury and liver regeneration in mice. J. Clin. Invest. 119(8), 2304-2316 (2009).
85. Astarcioglu I, Adam R, Gigou M, Isaac J, Bismuth H: High-levels of glycogen in the donor liver improve survival after liver-transplantation in rats. Transplant. Proc. 23(5), 2465-2466 (1991).
86. Caraceni P, Nardo B, Domenicali M et al.: Ischemia-reperfusion injury in rat fatty liver: role of nutritional status. Hepatology 29(4), 1139-1146 (1999).
87. Wernstedt I, Olsson B, Jernas M et al.: Increased levels of acylation-stimulating protein in interleukin-6-deficient (IL-6-/-) mice. Endocrinology 147(6), 2690-2695 (2006).